ArticleHaematologica2021

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.

Maxime Fayon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.